Ping An CSI Medicine and Medical Device Innovation ETF(516820) Rises 0.28%, Valuation Lower Than Over 96.09% of the Time in the Past Year

NewTimeSpace News, as of 10:12 on April 24, 2026, Ping An Medical Innovation ETF (516820) rose 0.28%, with its latest quoted price at 0.35 yuan. Looking at a longer timeframe, as of April 23, 2026, Ping An Medical Innovation ETF gained 4.45% over the past month. (The stocks listed above are merely index constituents and do not constitute any specific recommendation.)

In terms of liquidity, Ping An Medical Innovation ETF recorded an intraday turnover rate of 1.1%, with a trading volume of 19.3215 million yuan. Over a longer horizon, as of April 23, the ETF's average daily turnover over the past year stood at 50.0144 million yuan.

Regarding scale, the latest AUM of Ping An Medical Innovation ETF reached 1.756 billion yuan. (Data source: Wind)

Data shows that leveraged funds continue to position themselves. The latest margin purchase amount for Ping An Medical Innovation ETF reached 2.3499 million yuan, and the latest margin balance stood at 70.1369 million yuan. (Data source: Wind)

As of April 23, Ping An Medical Innovation ETF's net value increased by 5.83% over the past year. In terms of return capability, as of April 23, 2026, since its inception, the ETF achieved a highest single-month return of 27.10%, a longest consecutive gaining streak of three months with a cumulative gain of 18.70%, and an average return of 5.70% during up months. As of April 23, 2026, the ETF's annualized excess return over its benchmark over the past year was 2.21%.

In terms of drawdown, as of April 23, 2026, Ping An Medical Innovation ETF's relative drawdown versus its benchmark since the beginning of the year was 0.23%.

In terms of fees, Ping An Medical Innovation ETF has a management fee rate of 0.50% and a custody fee rate of 0.10%.

In terms of tracking accuracy, as of April 23, 2026, Ping An Medical Innovation ETF's tracking error since the beginning of the year was 0.038%.

From a valuation perspective, the latest price-to-earnings ratio (PE-TTM) of the CSI Pharmaceutical and Medical Device Innovation Index, which Ping An Medical Innovation ETF tracks, is only 24.55 times, placing it at the 3.91st percentile over the past year—meaning the valuation is lower than that of over 96.09% of the time in the past year, indicating a historically low level.

Ping An Medical Innovation ETF closely tracks the CSI Pharmaceutical and Medical Device Innovation Index. The CSI Pharmaceutical and Medical Device Innovation Index selects 30 listed company securities from the healthcare and pharmaceutical industry that have relatively strong profitability and certain growth and R&D innovation capabilities as index constituents, in order to reflect the overall performance of pharmaceutical and medical device listed company securities that combine profitability with growth.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.